CRBP vs. CMPX, AQST, ITOS, ETON, VIGL, HUMA, CYRX, ATXS, CKPT, and ARCT
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Compass Therapeutics (CMPX), Aquestive Therapeutics (AQST), iTeos Therapeutics (ITOS), Eton Pharmaceuticals (ETON), Vigil Neuroscience (VIGL), Humacyte (HUMA), CryoPort (CYRX), Astria Therapeutics (ATXS), Checkpoint Therapeutics (CKPT), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry.
Corbus Pharmaceuticals vs. Its Competitors
Corbus Pharmaceuticals (NASDAQ:CRBP) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.
64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 3.6% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 29.8% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Corbus Pharmaceuticals currently has a consensus target price of $50.88, indicating a potential upside of 498.53%. Compass Therapeutics has a consensus target price of $12.67, indicating a potential upside of 322.22%. Given Corbus Pharmaceuticals' higher probable upside, research analysts clearly believe Corbus Pharmaceuticals is more favorable than Compass Therapeutics.
Corbus Pharmaceuticals has higher earnings, but lower revenue than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Corbus Pharmaceuticals had 1 more articles in the media than Compass Therapeutics. MarketBeat recorded 2 mentions for Corbus Pharmaceuticals and 1 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.18 beat Corbus Pharmaceuticals' score of 0.85 indicating that Compass Therapeutics is being referred to more favorably in the news media.
Corbus Pharmaceuticals' return on equity of -36.87% beat Compass Therapeutics' return on equity.
Corbus Pharmaceuticals has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.
Summary
Corbus Pharmaceuticals beats Compass Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CRBP) was last updated on 7/18/2025 by MarketBeat.com Staff
